Market Assessment
In Q1/2019, DUR-928, the lead investigative drug candidate for Durect (DRRX), joins the list of more than 30 drug candidates in clinical development for NASH in 2019. As an early stage test drug candidate, DUR-928 is still a few years away from demonstrating its potential clinical efficacy in biopsied NASH. Given the complexity of NASH, its multi-factorial pathways and histopathological diversity of NASH patients, it's very obvious that drug candidates with diverse mechanisms are needed. As an endogenous sulfated oxysterol that could epigenetically “switch off” potent inflammatory and apoptotic responses associated